Scott S. Emerson, M.D., Ph.D.
Emerson Statistics Home
RCTdesign / S+SeqTrialTM
Scott's UW Faculty page
Scott collaborates or consults on a broad range of clinical trials and other biostatistical areas. His participation as member or chair of Data Monitoring Committees for more than 75 clinical trials aligns closely with his research interests in the design, monitoring, and analysis of sequential and adpative clinical trials. He has also served on governmental advisory committees reviewing the design of randomized clinical trials, as well as on FDA advisory committees reviewing clinical trial results.
Scott's biostatistical collaborations and consultations have covered a broad spectrum of diseases including
Scott has collaborated on randomized clinical trials directed toward efficacy / effectiveness, noninferiority, equivalence, biosimilarity, and/or safety. These RCT often involved multiple treatments, multiple doses, and/or multiple endpoints. Designs included parallel arms, cross-over, cluster randomization (including cross-over), fully factorial designs, and partial factorial designs. RCT were often monitored with formal sequential adaptive rules that allowed sample size re-estimation, dropping dose groups or treatments, adaptive enrichment, and/or early termination for efficacy, futility, and/or safety.
©2005-17 Scott S. Emerson and emersonstatistics.com|
email questions or comments about this site